X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

canSERV Offers Cancer Research Solutions Throughout Europe

Content Team by Content Team
17th September 2022
in News, Research & Development

Brussels marks the beginning of the European canSERV initiative, which aims to defragment the European cancer research landscape. CanSERV will give academia and business exposure to cross-cutting services and assistance from fundamental science up to clinical application over the next three years to promote individualised treatment for cancer patients.

Within the coming months, the unified platform that will house all of the participating infrastructures’ services will go live. In order to deliver services in a cross-border, coordinated way, canSERV will integrate, coordinate, and align current cancer and related research infrastructures. The critical mass of specialists and cutting-edge services provided by canSERV RIs and their extended networks will be tapped into in this way.

By providing cutting-edge services to cancer researchers, the EU-funded canSERV collaboration will help achieve the objectives of the EU Cancer Mission. Through canSERV’s single, unified international access platform, which will be developed to combine special cancer research services from all consortium partners, funded services can be requested.

For the benefit of people in Europe and beyond, the consortium is dedicated to maintaining long-term, continually providing access to present and future oncology services.

Key Objectives of canSERV

  • Over the next three years, to provide at least 200 separate, distinctive Personalized Oncology (PO) relevant and valued cutting programs for life science research in Europe.
  • To create a single, uniform, global access platform for making service and training requests.
  • To guarantee that any oncology-related data provided complies completely with the FAIR principles, complements other pertinent EU efforts, and works in tandem with them, such as EOSC, UNCAN.eu.
  • To continue the network and consolidate resources for the provision of oncology-related services when the project is over.

Overall, canSERV will hasten the conversion of theoretical knowledge into individualised oncology clinical practise, allowing cancer patients to obtain treatments and products more quickly and easily.

Additional project specifics

The EU Cancer Mission is supported by and aligned with canSERV. Interdisciplinary approaches may be the secret to advancing cancer research and identifying novel treatment options, according to the European Commission, which declared this mission last year. By offering novel, interdisciplinary, and personalised oncology services throughout the full cancer continuum, the canSERV initiative directly addresses this. As a result, all EU members and beyond will have access to a wide range of onco-research infrastructure services.

Prof. Jens K. Habermann, Director General of the BBMRI-ERIC in Graz and canSERV Coordinator, says that a more efficient, organised, and defragmented European oncology RI landscape will be produced thanks to the canSERV collaboration, which will also cater to the demands of EU academic and industrial customers.

The provision of top-notch services that are beneficial to all significant stakeholders, including researchers, universities, institutes, prominent SMEs, and European research consortia, is essential to canSERV. The goal is to encourage creative R&D initiatives, speed up the creation of cancer patient solutions across Europe, and make new and specialised research services accessible to the cancer research community.

The interdisciplinary canSERV consortium includes 19 partners from top EU Research Infrastructure Consortia (ERICs), Research Infrastructures (RIs), scientific societies, and patient organisations. Each partner offers canSERV special services and innovations.

CanSERV will offer the broadest and most exhaustive portfolio in cancer research thanks to the transnational cooperation and synergy of the consortium, significantly advancing scientific excellence in Europe and beyond. Open requests for funded services from the global cancer community will be made over the shared platform and extensively publicised in the cancer community.

Previous Post

Use of 2 COVID Therapies Is Highly Discouraged By The WHO

Next Post

CHMP Endorses Beyfortusfrom Sanofi And Astrazenecas For RSV

Related Posts

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Drugs Gain From Tardigrade Proteins, Says Research
Drug Development

Pharma Drugs Gain From Tardigrade Proteins, Says Research

22nd March 2023
Next Post

CHMP Endorses Beyfortusfrom Sanofi And Astrazenecas For RSV

Latest News

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In